Citadel Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-44,686
| Closed | -$152K | – | 10222 |
|
|
2018
Q3 | $152K | Sell |
44,686
-83,417
| -65% | -$301K | ﹤0.01% | 8390 |
|
|
2018
Q2 | $482K | Buy |
128,103
+88,501
| +223% | +$431K | ﹤0.01% | 6432 |
|
|
2018
Q1 | $162K | Sell |
39,602
-201,070
| -84% | -$936K | ﹤0.01% | 7495 |
|
|
2017
Q4 | $1.12M | Buy |
240,672
+89,889
| +60% | +$495K | ﹤0.01% | 4507 |
|
|
2017
Q3 | $1.07M | Buy |
150,783
+42,668
| +39% | +$307K | ﹤0.01% | 4218 |
|
|
2017
Q2 | $782K | Sell |
108,115
-40,051
| -27% | -$250K | ﹤0.01% | 4466 |
|
|
2017
Q1 | $912K | Buy |
148,166
+100,857
| +213% | +$553K | ﹤0.01% | 4144 |
|
|
2016
Q4 | $277K | Buy |
+47,309
| New | +$259K | ﹤0.01% | 5801 |
|
|
2016
Q3 | – | Sell |
-163,016
| Closed | -$879K | – | 8089 |
|
|
2016
Q2 | $1.08M | Buy |
163,016
+70,066
| +75% | +$392K | ﹤0.01% | 3458 |
|
|
2016
Q1 | $434K | Buy |
92,950
+92,949
| +9,294,900% | +$371K | ﹤0.01% | 4604 |
|
|
2015
Q4 | $0 | Sell |
1
-41,351
| -100% | -$196K | ﹤0.01% | 9477 |
|
|
2015
Q3 | $146K | Buy |
41,352
+15,079
| +57% | +$101K | ﹤0.01% | 6538 |
|
|
2015
Q2 | $262K | Sell |
26,273
-626
| -2% | -$6.71K | ﹤0.01% | 5945 |
|
|
2015
Q1 | $342K | Sell |
26,899
-88,094
| -77% | -$1.13M | ﹤0.01% | 5467 |
|
|
2014
Q4 | $1.63M | Sell |
114,993
-112,894
| -50% | -$1.75M | ﹤0.01% | 3164 |
|
|
2014
Q3 | $3.13M | Buy |
227,887
+209,075
| +1,111% | +$3.2M | ﹤0.01% | 2419 |
|
|
2014
Q2 | $289K | Sell |
18,812
-187,149
| -91% | -$2.65M | ﹤0.01% | 5106 |
|
|
2014
Q1 | $3.51M | Buy |
205,961
+37,224
| +22% | +$562K | ﹤0.01% | 2077 |
|
|
2013
Q4 | $2.19M | Buy |
168,737
+126,900
| +303% | +$1.52M | ﹤0.01% | 2463 |
|
|
2013
Q3 | $423K | Sell |
41,837
-21,284
| -34% | -$189K | ﹤0.01% | 3981 |
|
|
2013
Q2 | $472K | Buy |
+63,121
| New | +$493K | ﹤0.01% | 3896 |
|
Citadel Advisors's KERX Position: Q4 2018 in Review
Citadel Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 44,686 shares — an estimated $152K sold.
Citadel Advisors first reported a position in KERX in Q2 2013 and held it in 21 quarters. The position peaked at $3.51M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Citadel Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Citadel Advisors sold 44,686 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $152K.
- Citadel Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 21 quarters.
- Citadel Advisors's Keryx Biopharmaceuticals Inc position peaked at $3.51M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.